SCHEMBL2471006

SCHEMBL2471006

O=C(CCc1ccccc1)N1CCC(C(=O)N2CCN(c3ccc(Cl)cc3)CC2)(c2ccccc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.75
KMT2A Q03164 3/20 0.75
MEN1 O00255 2/20 0.75
ME2 P23368 1/20 0.60
ME1 P48163 1/20 0.60
ME3 Q16798 1/20 0.60
GFER P55789 2/20 0.58
HTR7 P34969 4/20 0.56
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
HTR1A P08908 2/20 0.55
GRM5 P41594 1/20 0.53
MMP2 P08253 1/20 0.52
MMP13 P45452 1/20 0.52
ADAMTS5 Q9UNA0 1/20 0.52
ATM Q13315 1/20 0.52
NPSR1 Q6W5P4 2/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2824683 0.87 MAPT (1.00) MAPTKMT2AMEN1ME2ME1
SCHEMBL2471018 0.86 KMT2A (0.57) MAPTKMT2AMEN1ME2ME1
SCHEMBL7168690 0.84 HSD11B1 (0.62) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2516139 0.82 ALDH1A1 (0.58) MAPTKMT2AMEN1ME2ME1
SCHEMBL10252724 0.81 ALDH1A1 (0.55) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2522603 0.81 ALDH1A1 (0.55) MAPTKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2470194 0.80 ENPP2 (0.62) MAPTKMT2AMEN1ME2ME1
SCHEMBL2474161 0.80 ALDH1A1 (0.76) KMT2AME2ME1ME3HTR7
SCHEMBL2472473 0.80 MAPT (0.56) MAPTKMT2AMEN1HTR7SMN1; SMN2
SCHEMBL2700497 0.78 NPC1 (0.63) MAPTKMT2AMEN1ME2ME1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP claimed
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 MAPT 3715/4885KMT2A 957/4885MEN1 3501/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 MAPT 3715/4885KMT2A 957/4885MEN1 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.